|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
An increased level of Nectin-4 along with representative metastatic (CD-44, Sca1, ALDH1, Nanog) and angiogenic (Ang-I, Ang-II, VEGF) markers were noted in metastatic tumors (local and distant) in comparison to primary tumors that were correlated with different grades of tumor progression.
|
31617074 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANGPT1, ANGPT2 and 3 hub proteins (EGFR, HSP90AA1, RB1) in the PPI network were associated with the survival rates of several tumors.
|
28043142 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Antitumor activity was evaluated in athymic nude mice bearing subcutaneous DLD1 xenograft tumors and treated with anti-VEGF (B20), anti-Ang-2 (LC06) and anti-VEGF/Ang-2 (CrossMab) antibodies.
|
31394786 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ang II stimulation increased the expression of Ang II receptor 1 (AT1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), tumor growth factor-β (TGF-β) mRNA, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and the levels of hydrogen peroxide (H₂O₂) and superoxide anion (•O₂<sup>-</sup>) and reduced anti-oxidant enzyme activity.
|
30678135 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We measured disease activity (weight loss, stool consistency, fecal occult blood) during the study and at sacrifice, collected blood for cytokine/biomarker (Ang2, interleukin [IL] 1-β, IL-6, tumor necrosis factor α [TNFα], and VEGF-C) enzyme-linked immunosorbent assay analysis, measured colon length, and assessed tumor burden.
|
31173626 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression levels of genes relevant for angiogenesis [angiopoietin (ANGPT)1, ANGPT2, fibroblast growth factor (FGF)1, FGF2, epidermal growth factor, placental growth factor, VEGFA and DLL4] were detected by reverse transcription‑quantitative PCR using RNA extracted from the frozen tissues of four tumors with low and four tumors with high NICD expression.
|
31578584 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This corresponds with a decrease in Vegfa-stimulated response, but an increase in Vegfa+Ang2- or conditioned medium from tumor cell-stimulated cellular/angiogenic responses, mimicking responses in end-stage tumors with elevated Ang2 levels.
|
31189647 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Arid1a-deficiency also sensitizes tumors to Ang2 blockade by sorafenib treatment.
|
29113912 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
VEGF-A and Ang-2 concentrations were significantly higher in tumor patients than in healthy controls in both samples (p < .01).
|
29397265 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Total incidence of Ang-2 expression in the cancerous tissues was up to 91.8 % (112 of 122) with significantly higher (χ<sup>2</sup>=103.753, <i>P</i><sup>2</sup>=7.883, <i>P</i>=0.005), differentiation degree (χ<sup>2</sup>=4.554, <i>P</i>=0.033), tumor node metastasis (TNM) staging (χ<sup>2</sup>=5.039, <i>P</i>=0.025), and 5-year survival rate (χ<sup>2</sup> =11.220, <i>P</i><sup>2</sup>=18.881, <i>P</i><sup>2</sup>=0.81, <i>P</i>=0.776) or III & IV (χ<sup>2</sup>=1.845, <i>P</i>=0.174).
|
29560103 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum Ang-2 may be a useful tumor marker in predicting liver cancer prognosis.
|
29253494 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this Perspective, we outline the roles of VEGF and ANG2 in tumour immune evasion and progression, and discuss the evidence indicating that antiangiogenic agents can normalize the TME.
|
29508855 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with control samples, the Ang1 expression of the transplanted tumor in both the hyperplasia and proliferative phases was stably low (p<0.05), while expressions of Ang2 and Tie2 were both stably high (p<0.05).
|
28387902 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In subcutaneous xenograft models of cervical cancer, downregulation of Ang-1 and Ang-2 attenuated tumor growth.
|
28720059 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies have shown that angiopoietin 2 (Ang2), a pro-angiogenic protein, is involved in the pathogenesis of this tumor.
|
28370338 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ipilimumab increased, and ipilimumab plus bevacizumab decreased, tumor vascular ANGPT2 expression in a subset of patients, which was associated with increased and decreased tumor infiltration by CD68<sup>+</sup> and CD163<sup>+</sup> macrophages, respectively.
|
28003187 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously reported that Kaposi's sarcoma-associated herpes virus (KSHV) infection of endothelial cells induces the cytokine angiopoietin-2 (Ang-2) to promote migration of monocytes into tumors.
|
28750175 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
According to our results, higher levels of serum Ang-2 were associated with the later stage of tumor.
|
28906403 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results showed that the expression levels of vascular endothelial growth factor A (VEGFA), angiopoietin-2 (ANGPT2), and tissue plasminogen activator (PLAT) were suppressed in ADAM9-silenced cells, which in turn leads to decreases in angiogenesis, vascular remodeling, and tumor growth in vivo.
|
29118335 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ang-2 expression was significantly associated with the tumor grade and stage, as well as the MIB-1, Bcl-2, and VEGFR3 expression (P = .042, P = .019, P = .039, P = .013, and P = .005, respectively).
|
27554585 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Angiopoietin 2 in placentation and tumor biology: The yin and yang of vascular biology.
|
28372817 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For lenvatinib-treated patients, interaction-term analyses revealed that low baseline Ang2 level was predictive of tumour shrinkage (P<sub>interaction</sub> = 0.016) and PFS (P<sub>interaction</sub> = 0.018).
|
28237867 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TEMs significantly increased in EOC patients and were recruited to tumour loci by the increased Ang2.
|
28898232 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we investigated the role of DARPP-32 proteins in regulating angiopoietin 2 (ANGPT2) and promoting tumour angiogenesis.
|
25779598 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The initial step in the metastasis and transition of tumors is epithelial-mesenchymal transition (EMT)-induced angiogenesis, which can be mediated by angiopoietin 2 (ANG2), a key regulatory factor in angiogenesis.
|
27492854 |
2016 |